WO2020206404A9 - Systèmes de traitement cutané - Google Patents

Systèmes de traitement cutané Download PDF

Info

Publication number
WO2020206404A9
WO2020206404A9 PCT/US2020/026788 US2020026788W WO2020206404A9 WO 2020206404 A9 WO2020206404 A9 WO 2020206404A9 US 2020026788 W US2020026788 W US 2020026788W WO 2020206404 A9 WO2020206404 A9 WO 2020206404A9
Authority
WO
WIPO (PCT)
Prior art keywords
encaser
therapeutic composition
skin
liner
body part
Prior art date
Application number
PCT/US2020/026788
Other languages
English (en)
Other versions
WO2020206404A1 (fr
Inventor
Deanna MONTROSE
Original Assignee
Paraffinusa, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paraffinusa, Llc filed Critical Paraffinusa, Llc
Priority to JP2021560289A priority Critical patent/JP2022522232A/ja
Priority to KR1020217036255A priority patent/KR20210150490A/ko
Priority to EP20783239.5A priority patent/EP3946548A4/fr
Priority to CA3135986A priority patent/CA3135986C/fr
Priority to CN202080043240.3A priority patent/CN113993573A/zh
Publication of WO2020206404A1 publication Critical patent/WO2020206404A1/fr
Publication of WO2020206404A9 publication Critical patent/WO2020206404A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/10—Wearable devices, e.g. garments, glasses or masks
    • A—HUMAN NECESSITIES
    • A45—HAND OR TRAVELLING ARTICLES
    • A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
    • A45D26/00—Hair-singeing apparatus; Apparatus for removing superfluous hair, e.g. tweezers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H33/00—Bathing devices for special therapeutic or hygienic purposes
    • A61H33/04—Appliances for sand, mud, wax or foam baths; Appliances for metal baths, e.g. using metal salt solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H33/00—Bathing devices for special therapeutic or hygienic purposes
    • A61H33/04—Appliances for sand, mud, wax or foam baths; Appliances for metal baths, e.g. using metal salt solutions
    • A61H2033/047—Paraffin or wax baths
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2205/00—Devices for specific parts of the body
    • A61H2205/06—Arms
    • A61H2205/065—Hands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H2205/00—Devices for specific parts of the body
    • A61H2205/12—Feet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3368—Temperature

Definitions

  • Wax-based therapeutic compositions applied externally to the skin may be used to condition and soften skin, relieve joint pain, and improve a variety of skin conditions.
  • Wax-based therapeutic compositions may be heated to melt the wax and to heat the skin or body part to which it is applied for pain relief.
  • Current methods of melting bulk quantities of wax-based therapeutic compositions may take approximately two to three hours, impeding the delivery of the therapy to a person.
  • repeated heating-cooling cycles of wax-based therapeutic compositions for skin therapy may reduce the effectiveness of the composition over time. Additionally, overheating and uneven heating and cooling of the wax-based therapeutic compositions poses a significant safety risk for burning the person’s skin.
  • a convenient and hygienic skin therapy system comprising an encaser, one or more therapeutic compositions, a sealing means and optional accessories is disclosed.
  • a method of using such a skin therapy system is also provided.
  • the skin therapy system and the use thereof provides an effective, efficient and safe therapeutic approach.
  • FIG. 1 illustrates an exemplary therapy system comprising a glove
  • FIG. 2 shows a top view illustrating the therapy system comprising a glove
  • FIG. 3 illustrates an exemplary therapy system comprising a boot
  • FIG. 4A shows a perspective view illustrating a container for holding and heating the therapy system
  • FIG. 4B shows a planar view illustrating the container for holding and heating of the therapy system
  • FIG. 5 shows a cross-sectional view along section 5-5 of FIG. 4B;
  • FIG. 6 A shows a planar view illustrating the container for holding and heating the therapy system
  • FIG. 6B shows a perspective view of the therapy system as a pre-packaged kit
  • FIG. 7 shows a perspective view illustrating the therapy system comprising a glove
  • FIG. 8 shows a diagrammatic view illustrating heating of a therapeutic composition
  • FIG. 9 illustrates a method of using the therapy system
  • FIG. 10 is a flow chart illustrating a method of heating the therapy system
  • FIGS. 11A and 11B show additional dimensions and details of the therapy system comprising a glove and a boot;
  • FIGS. 12A and 12B illustrate an exemplary thermochromatic ink applied to the encaser of the therapy system
  • FIG. 13 illustrates a therapy system with thermochromatic ink indicating uneven heat in the therapeutic composition
  • FIG. 14 illustrates an exemplary therapy system with heat-sealed edges
  • FIG. 15 is an exemplary cross-section view of a skin therapy system, which illustrates various methods of skin therapy; and [0023] FIG. 16 is an exemplary cross-section view of a skin therapy system, which illustrates various methods of transdermal delivery of a medicinal.
  • the present technology may be described in terms of functional block components and various processing steps. Such functional blocks may be realized by any number of components configured to perform the specified functions and achieve the various results.
  • methods and systems according to various aspects of the present technology may employ various materials for containing heat-stable therapeutic compositions which may be practiced in conjunction with any number of compositions and procedures for treating pain and inflammation of joints and other body parts and the systems described are merely exemplary applications for the technology.
  • Various representative implementations of the present technology may be applied to any portion of the human body for the treatment of skin, pain, injury, and/or inflammatory medical conditions.
  • the encaser 120 comprises an internal volume for receiving a person’s body part, such as a hand, foot, and/or elbow.
  • the encaser 120 may comprise a fastener that may be configured to attach or hold the encaser 120 to the desired portion of the body.
  • the encaser liner 116 forms a second internal volume for receiving the body part and is positioned within the internal volume of the encaser 120 and helps with the substantially even distribution of the therapeutic composition 106 throughout the encaser 120 in a space formed between an inner surface of the encaser 120 and an outer surface of the encaser liner 116.
  • the therapeutic composition 106 may comprise a wax with any number of cosmetic and/or pharmaceutical compositions that may treat problems of the skin and/or pain, injury, and/or inflammation of the body.
  • the temperature indicator 118 may comprise any temperature activated device, ink, or other indicator that may be applied to the encaser 120, the encaser liner 116, and/or the therapeutic composition 106 that functions to indicate the temperature of the therapeutic composition 106 to ensure safe use of the therapy system.
  • Various embodiments of the skin therapy system 100 may be configured as a sealed, reusable container for a therapeutic composition 106 disposed inside the encaser 120.
  • an outer peripheral edge of the encaser liner 116 may be coupled to an inner surface of the encaser 120 along an outer peripheral edge of the encaser 120 such that the encaser liner 116 retains the general shape of the encaser 120 while also creating a tillable space or region between an inner surface of the encaser 120 and the outer surface of the encaser liner 116.
  • the therapeutic composition 106 may then be disposed within the tillable space prior to use.
  • the encaser liner 116 remains stretched to edges of the encaser 120 regardless of the composition and/or temperature of the therapeutic composition 106. This configuration prevents the contraction, or “balling up” of the encaser liner 116 when the body part is removed from the encaser 120 and/or when the therapeutic composition 106 cools after use.
  • the sealed configuration of the skin therapy system 100 allows it to be heated in a variety of apparatus while avoiding contamination of the enclosed encaser liner 116 and therapeutic composition 106.
  • MRSA methicillin-resistant Staphylococcus aureus
  • the encaser liner 116 is not dipped into a communal container of liquid paraffin (sometimes referred to as a “paraffin pot”). Instead, the Tillable space is filled with the therapeutic composition 106 and sealed into place.
  • the encaser 120 may be formed into the shape of a desired body part such as: a hand, a foot, an elbow, a knee, a patch or strip suitable to attach to the torso or skull, and/or any other body part.
  • the encaser 120 may be formed in the shape of a glove, a mitten, a muff, a fingerstall, a sock, a slipper, a shoe, a booty, a bonnet, a strip, a knee support, a skullcap, and/or a mask in the form of all or part of the face or head, or any other suitable forms and shapes.
  • the encaser 120 is hand shaped.
  • the encaser 120 is foot shaped.
  • the encaser 120 may comprise any suitable encaser materials to contain the therapeutic composition 106 such as carbon-fiber, plastic, transparent/translucent polymer such as polyethylene, plastic film, metal foil, depending on design requirements and heating sources.
  • the encaser 120 may be made of elastic material that allows for expanding or stretching. The material used to make the encaser 120 is heat-durable and does not release toxic chemicals upon heating.
  • the material of the encaser 120 may be formed of at least two layers of the encaser material.
  • the encaser material may be adhered together to appear as a single layer.
  • a temperature indicator 118 such as a thermochromatic material comprising ink and/or other markings such as a trademark may be printed, stamped, and/or adhered to one layer of the encaser material.
  • the encaser material may then be adhered to another layer of encaser material such that the thermochromatic material or other marking may be sealed between the two layers of the encaser material.
  • the encaser 120 may also be configured to accommodate body parts suffering from injury or restricted movement.
  • the encaser 120 may be formed for a hand in which the user may not have full range of motion or restricted movements in the fingers such that the fingers may not be comfortably placed in a standard glove configuration.
  • the encaser 120 may accommodate two or more fingers in a single section while allowing one or more other fingers to be positioned within their own section.
  • the encaser 120 may also comprise elements, such as a strap, configured to help position a finger or body part in a desired position during treatment.
  • the body part shaped encaser 120 may be unisized, such that it references to the average body part size acceptable in the industry. In one embodiment, the encaser 120 may be unisized for women’s hands or feet. In one embodiment, the encaser 120 may be unisized for men’s hands or feet. In one embodiment, the encaser 120 may be stretchable such that it can fit for any size of body part of a man and/or a woman. The encaser 120 may also be manufactured in a series of sizes that are standard in the industry, such like the standard sizes for gloves, shoes, and other similar products.
  • the encaser 120 may have in-folds, which provide a three-dimensional shape that better accommodates the shape and dimension of a body part upon usage.
  • the encaser 120 is foot-shaped, with an in fold providing a sole of a slipper, a boot, a shoe when unfolded.
  • FIG. 1 shows a schematic diagram depicting multiple embodiments of a single-use body part-shaped encaser 120 to exemplify the skin therapy system 100.
  • Single-use body part-shaped encaser 120 utilizes at least one single-use glove 102 or, alternately, at least one single-use boot 104.
  • Such a single-use glove 102 or single-use boot 104 comprises a hand or foot encaser 120 for encasing at least one human hand or foot.
  • Each single-use glove 102 or each single- use boot 104 contains at least one therapeutic composition 106, which may be quickly heated (from about one to about four minutes) by various heating sources including, but not limited to, a microwave oven 108.
  • each single-use glove 102 or single-use boot 104 is structured and arranged to be a sanitary one-time-use disposable product as further described herein.
  • sanitary one-time-use disposable product as further described herein.
  • other device configurations such as, for example, arm wraps, leg wraps, etc.
  • skin therapy system 100 may function to warm the skin to help soften dead skin (thus facilitating exfoliation).
  • various embodiments of skin therapy system 100 may function to warm joints and assist with circulation.
  • FIG. 2 shows a top view, illustrating a single-use glove 102 of the skin therapy system 100.
  • Single-use glove 102 may comprise therapeutic composition 106 positioned in each finger portion 111 and thumb portion 115 and at the palm region 123, as shown.
  • the palm region 123 of single use glove 102 comprises at least one first quantity of therapeutic composition 106.
  • the therapeutic composition 106 is placed within the interior of the single-use glove 102 in the palm region 123.
  • each single-use glove 102 comprises at least one second quantity of therapeutic composition 106 placed within the interior of the glove in each of the finger portions 111 and thumb portion 115, as shown.
  • the therapeutic composition 106 in the palm region and the hand digit portions 111 and 115 may be the same or different.
  • single-use glove 102 comprises one substantially flexible containment wall 107 having an interior portion 113 structured and arranged to contain at least one palm composition 130, a finger composition 132, and a thumb composition 134.
  • Containment wall 107 further comprises an access opening, which is a hand aperture 140 in the single-use glove 102 embodiment.
  • Hand aperture 140 may permit a user to insert a hand into the single-use glove 102, during use.
  • Hand aperture 140 may comprise a width, when flat, of about seven inches.
  • Single-use glove 102 may further comprise at least one temperature indicator 118, optionally positioned at any finger-tip, at the thumb-tip, at the palm area, or anywhere the temperature indicator 118 may sense the temperature of the therapeutic composition 106 enclosed in the single-use glove 102.
  • FIG. 3 shows a top view illustrating a single-use boot 104 of the skin therapy system 100.
  • the single-use boot 104 comprises a therapeutic composition 106 positioned in the ankle region 145, and/or toe region, of the single use boot 104.
  • Therapeutic composition 106 in ankle region 145 of single-use boot 104 may comprise at least one ankle composition 136.
  • the single-use boot 104 comprises at least one foot aperture 142. Foot aperture 142 permits the user to insert a foot into the single-use boot 104, during use. Foot aperture 142 may comprise a width, when flat, of about ten inches.
  • FIGS. 11A and 11B depict exemplary dimensions and details of an embodiment of a single-use glove 102 and single-use boot 104 for the skin therapy system 100.
  • the single-use boot 104 (without any therapeutic composition) is also commercially available for purchase, for example, the Sani-boot made by Keystone, or similar products through Pro-safety of Milwaukee WI.
  • the therapeutic compositions 106 applicable for the skin therapy system 100 may be wax-based, liquid-based, or gel-based; all of which are to be spread evenly inside the encaser in a pre-determined amount prior to skin application.
  • a wax- based composition the solidified composition is spread into a thin layer in a body part shaped encaser 120 with the shape essentially the same as the encaser 120.
  • a liquid based composition a predetermined amount of the composition sufficient to cover targeted skin area is enclosed in a body part shaped encaser.
  • the therapeutic composition 106 is contained inside the encaser 120 without the risk of leaking, spill, evaporation, or cross-contamination, and can readily be applied to the skin area without the need of further spreading while providing nearly even and direct contact to skin under treatment.
  • the therapeutic compositions 106 applicable for the skin therapy system 100 may comprise various ingredients, which are selected according to their physical, chemical, or pharmaceutical characteristics suitable for the skin therapy system 100 and therapeutic targets.
  • the wax-based, liquid-based, or gel- based therapeutic composition 106 is pre-packaged into the encaser of the skin therapy system 100 and may or may not require heating prior to skin application. In other embodiments, the wax-based, liquid-based, or gel-based therapeutic composition may be installed into the encaser 120 customarily prior to a therapy session.
  • Each encaser 120 of the skin therapy system 100 may comprise one or more therapeutic compositions 106.
  • the therapeutic composition 106 is positioned in a single-use body part shaped encaser 120 at time of manufacturing.
  • the therapeutic composition 106 is uniformly positioned in a single-use body part shaped encaser 120, such that the therapeutic composition 106 is spread about evenly as a thin layer throughout the encaser 120.
  • the therapeutic composition 106 in a body part shaped encaser 120 is a contiguous thin layer of solidified or gel-like form extending evenly to each interior portion 113 or region of an encaser 120.
  • the thickness of the contiguous thin layer of the composition may be between about 0.1 inch to about 1.5 inches.
  • a solid form therapeutic composition 106 of a quantity may be molded into a certain shape of certain size before positioned in a body part shaped encaser 120.
  • the therapeutic composition 106 of a quantity may be added in to a body part shaped encaser 120 when the therapeutic composition 106 is in a liquefied state, which then may solidify or undergo gelification with or without pressing or molding the composition into the shape of the encaser 120 upon cooling or sitting.
  • a quantity of a first therapeutic composition 106 is placed in each of the fingers and thumb portion 111, 115 of a hand shaped encaser 120, and a quantity of a second therapeutic composition 106 is placed in the palm region 123 of a single-use body part shaped encaser 120; wherein the first therapeutic composition 106 heats up at a slightly slower rate than the second therapeutic composition 106 placed in the palm region 123 such that, upon heating, all of therapeutic composition 106 placed into a hand shaped encaser 120 will heat up or melt about equally and reach a predetermined temperature at about the same time.
  • Even heating without overheating any portion of a therapeutic composition 106 may be important for even liquefaction of solid form therapeutic composition 106, and the safe use of the skin therapy system 100 to prevent skin injury due to excessive or uneven heat during the direct skin-composition contact in a skin therapy.
  • therapeutic composition 106 in each finger portion 111 may comprise at least one finger composition 132, or alternately, in thumb portion 115 at least one thumb composition 134.
  • Finger composition 132 may comprise enough therapeutic composition 106, when melted or heated, to substantially coat each finger portion 111 of single-use glove 102. In one embodiment, finger composition 132 comprises about one-half ounce of therapeutic composition 106.
  • Thumb composition 134 may comprise enough therapeutic composition 106, when melted or heated, to substantially coat the thumb portion 115 of single-use glove 102. In one embodiment, thumb composition 134 comprises about one ounce of therapeutic composition 106.
  • finger composition 132 and thumb composition 134 comprise at least one insert 135, which may be a bar as shown, or pellets, or a thin layer of solidified or gel like therapeutic composition 106.
  • finger composition 132 comprises an insert 135 such as a bar having a length of about three inches, a width of about one-half inch, and a thickness of about one-half inch.
  • thumb composition 134 comprises an insert 135 such as a bar having a length of about two-and one-half inches, a width of about one inch, and a thickness of about one- half inch.
  • Therapeutic composition 106 in the palm region 123 comprises at least one palm composition 130.
  • Palm composition 130 may comprise enough therapeutic composition 106, when melted or heated, to substantially coat the palm region 123 of single-use glove 102.
  • palm composition 130 comprises at least one insert of the therapeutic composition 106, which may be in a form of a circular disc, as shown, or a bar, or pellets, or an evenly spread out solidified or gel like thin layer.
  • palm composition 130 comprises two-and-one-quarter ounces of therapeutic composition 106.
  • palm composition 130 in a form of circular disk comprises a diameter of about four inches, and a thickness of about one-half inch.
  • the therapeutic composition 106 in ankle region 145 of single-use boot 104 may comprise at least one ankle composition 136.
  • ankle composition 136 comprises enough therapeutic composition 106, when melted, to substantially coat single-use boot 104.
  • Ankle composition 136 may comprise about six ounces of therapeutic composition 106.
  • ankle composition 136 is in a form of at least one insert, which may be a circular disc, as shown, or a bar, or pellets, or an evenly spread out solidified or gel like thin layer.
  • the ankle composition 136 in a form of circular disc comprises a diameter of about eight inches and a thickness of about one-quarter inch.
  • the therapeutic composition 106 is inserted as a contiguous thin layer of solidified or gel like form extending evenly throughout the ankle region 145, a toe portion of the encaser 120 and up to a bottom of a top section 125 proximate foot aperture 142.
  • Hand aperture 140 or foot aperture 142 may be sealed or partially sealed to prevent spilling of therapeutic composition 106 outside of the body part shaped encaser 120 during heating and application.
  • the apertures 140 and 142 are sealed by folding, a tongue in groove locking mechanism, removable tape or adhesive strips, removable adhesive, sewing, iron-on or heat seals, such that air or steam in the encaser may be released when the seal is removed and the encaser 120 is heated.
  • the apertures 140 and 142 are partially sealed to permit venting of any accumulated gases associated with heating of therapeutic composition 106. Other venting arrangements such as, for example, one-way vents, slits, re-sealable portals, etc., may also be applicable.
  • the apertures 140 and 142 are vacuum sealed, such that the encaser 120 stays air-free during heating so that heat and moisture in the encaser are retained, and the explosion or expanding of the encaser 120 during heating can be avoided.
  • the seal of a body part shaped encaser 120 may be removed by cutting, trimming, or tearing after heating and prior to skin application.
  • a closure 150, as best shown in FIGS. 4A-6A, of a sealing box 114 may be used to hold and seal hand aperture 140 and foot aperture 142 (shown in FIG. 6 A).
  • the top section 125 of the gloves 102 and boots 104 may have an extended length along respective wrist (glove) and ankle (boot) portions as shown in FIG.
  • each device may be folded over on the opened end (aperture) and placed in the sealing box 114, with the folded portion of the aperture 140, 142 aligned with the flap of the closure 150 of the sealing box 114 as shown in FIGS. 4A, 4B and 5.
  • the flap of the closure 150 is elevated with respect to the rest of single-use body part shaped device 120 when the closure 150 is in a closed position as shown in FIG. 5.
  • the sealing box 114 may further comprise at least one window 152 in addition to at least one closure 150 (FIG. 4A).
  • Window 152 permits viewing of temperature indicator 118 (described below), during heating, to visually determine the proper temperature.
  • Window 152 also permits viewing therapeutic composition 106, during heating, to visually determine complete melting of therapeutic composition 106.
  • one or more single-use therapy encasers 120 is placed in one sealing box 114.
  • an individual single-use encaser 120 is placed in one sealing box 114.
  • the sealing box 114 may be for single-use or may be used repeatedly.
  • the external sealing box 114 can be microwavable.
  • the microwavable sealing box 114 may comprise at least one microwave-safe material selected from cardboard, a wood-pulp material, carbon- fiber, microwavable plastics, ceramics, wood derivative materials, and any combination thereof.
  • the encaser liner 116 is used to help apply the therapeutic composition 106 to the user’s skin during treatment.
  • the encaser liner 116 may be configured to allow at least a portion of the therapeutic composition 106 to migrate from the tillable space through the encaser liner 116 itself and to the user’s skin.
  • the encaser liner 116 may have the same shape and dimension as the encaser 120 or be sized slightly smaller, such that the encaser liner 116 can be inserted into the encaser 120 with ease.
  • the encaser liner 116 may be made of material selected from paper, textile, non-woven fabrics, plastic fabrics, non-woven polypropylene fabrics, and any combination thereof.
  • the encaser liner 116 may be opaque or may have any level of transparency and may have any tint of color.
  • the addition of the encaser liner 116 provides a range of functions such as heat insulation, even heating, overheating spot prevention, moisture retaining, distribution, absorbency, resilience, stretch, softness, strength, cushioning, padding, filtering and sterility.
  • the encaser liner 116 provides a medium support or a holding agent for any form of the therapeutic composition 106 including, but not limited to, mud-based, clay -based, wax-based, liquid-based and gel -based compositions, such that the therapeutic composition 106 has reduced mobility within tillable space of the encaser 120.
  • the encaser liner 116 is made of paper sheet.
  • the encaser liner 116 is made of non-woven polypropylene fabric configured to allow one or more ingredients of the therapeutic composition 106 to migrate from the tillable space to the user’s skin during use.
  • a single-use body part shaped encaser 120 may further comprise a temperature indicator 118 for visually indicating the temperature range of a therapeutic composition 106 during and after heating. This feature is provided to assist in preventing overheating of therapeutic composition 106 and to monitor the temperature of the skin therapy system 100 during the therapy.
  • 126°F is a recognized temperature safety limit in the industry.
  • a therapeutic composition 106 with a temperature above 126°F is not suitable for direct application on top of skin.
  • the temperature indicator 118 may be a coating, a strip, a sticker, a label, a tape, or any other form that is applicable.
  • the temperature indicator 118 may be reversible or irreversible depending on the indications desired to be given.
  • Single-use body part shaped encaser 120 comprises at least one temperature indicator 118.
  • the temperature indicator 118 comprises at least one thermochromatic coating structured and arranged to visibly indicate internal therapeutic composition temperature of a respective body part shaped encaser 120 comprising therapeutic composition 106.
  • one or more temperature indicator 118 is located on the interior side of the encaser 120.
  • the temperature indicator 118 may be applied as a thermochromatic patch or sticker to the exterior surface of the encaser 120. The temperature indicator 118 functions to visually indicate the approximate temperature of therapeutic composition 106 such that the user is warned if the temperature is above or under a desired range of temperature.
  • the visual indication may be through a change of color, the disappearance of color, the appearance of color, a showing of a number presenting a temperature, a level of temperature, a range of temperature, and/or other number or text that conveys information about the temperature to the user.
  • Other temperature indicators may include pop-up notifiers or sound notifiers as known in the art.
  • the single-use glove 102 comprises at least one temperature indicator 118.
  • the temperature indicator(s) 118 may be positioned anywhere on the surface of the encaser, including on each fingertip, at the thumb-tip, and at the palm area of single-use glove 102.
  • the single-use boot 104 may also comprise at least one temperature indicator 118, positioned anywhere including at the ankle area and at the toe area of single-use boot 104.
  • both the thermochromatic coating 110 and the thermochromatic sticker 112 may change to at least one warning- temperature color, when therapeutic composition 106 exceeds at least one ideal temperature range.
  • the temperature indicator 118 may comprise a temperature activated ink.
  • the temperature activated ink may be sprayed, printed, stamped, and/or otherwise applied between two substrates of film that comprise the encaser 120. The two substrates of film may then be laminated together to form the material for the encaser 120.
  • the use of the temperature indicator 118 comprising the temperature activated ink embedded between the two layers of laminated film that comprise the encaser 120 may allow the skin therapy system 100 to be heated in hot water baths in hospitals or other clinical setting and prevent the temperature activated ink from washing or fading away.
  • temperature indicator 118 comprising the temperature activated ink may be applied onto the film in discrete patches, such as a design and/or trademark throughout the therapy system 100.
  • FIG. 12B illustrates another embodiment in which the temperature activated ink may be applied evenly onto the film.
  • a change in the color of the temperature indicator 118 may indicate that the therapeutic composition 106 inside the encaser 120 may be too hot for safe use and may cause bums to the skin. In that case, the user may allow the therapeutic composition 106 to cool to a safe temperature as indicated by a return of temperature indicator 118 to its previous color before applying the skin therapy system 100 to the skin.
  • FIG. 12A temperature indicator 118 comprising the temperature activated ink may be applied onto the film in discrete patches, such as a design and/or trademark throughout the therapy system 100.
  • FIG. 12B illustrates another embodiment in which the temperature activated ink may be applied evenly onto the film.
  • a change in the color of the temperature indicator 118 may indicate that the therapeutic composition 106 inside the encaser 120 may
  • a fastener may attach and stabilize the encaser to the skin area for a period of therapy time.
  • the fastener may be chosen from adhesive tape, straps, strings, elastic material, fabric tape, tubing, or other functional devices.
  • the fastener may or may not be included in the skin therapy system.
  • a body shaped encaser 120 comprises a fastener.
  • FIG. 7 shows a perspective view of an exemplary single-use glove 102 of the skin therapy system 100
  • FIG. 9 shows a method using the single-use glove 102 wherein the single-use glove 102 comprises at least one aperture seal 144.
  • aperture seal 144 further comprises at least one strap 146, which includes at least one adhesive strip 148.
  • Strap 146 and strip 148 may vary in width and length.
  • strap 146 has a length of about seven inches and a width of about one-half inch. In some embodiments, strap 146 is attached to single-use body shaped encaser 120 through at least one seam. Alternately, strap 146 may be attached to single-use body shaped encaser 120 by heat welding or mechanical fastener. In one embodiment, adhesive strip 148 comprises a length of from about one-half-inch to about four-inches.
  • the skin therapy system 100 may further comprise one or more external padding, outer pouch, coverlet, harness, heating or temperature maintaining element, stand-alone user instruction, or instruction attached to the single use body part shaped encaser.
  • the instruction may be in a print, a writing, a disk, or any other suitable medium.
  • one or more heating or temperature maintaining elements is attached to the exterior surface of the body part shaped encaser of the skin therapy system 100.
  • the encaser liner 116 may be positioned between a first substrate of film 1410 and a second substrate of film 1415, which form the encaser 120.
  • the encaser liner 116 may extend to the edges of the first substrate of film 1410 and the second substrate of film 1415.
  • Outer peripheral edges of the encaser liner 116, the first substrate of film 1410, and the second substrate of film 1415 may be sealed together to form a first hermetic seal 1400 along the outer edges of the skin therapy system 100. This also forms the tillable space between an inner surface of the first and second substrates of film 1410, 1415 and the encaser liner 116.
  • the Tillable space may be filled with the therapeutic composition 106 and subsequently sealed in place with at least one additional hermetic seal 1402 positioned near a wrist portion of the encaser 120.
  • the hermetic seals 1400, 1402 are used to keep the therapeutic composition 106 within the fillable space and around the encaser liner 116 during and between uses.
  • Access to the internal volume of the encaser 120 is accomplished via the hand aperture 140 that allows the user to insert their hand into the encaser liner 116.
  • the hand aperture 140 may be positioned at an end most location of the encaser 120 to allow a user’s hand to be inserted into and removed from the internal volume of the encaser 120 similar to a regular glove.
  • a closure element 1425 may be positioned between the hand aperture 140 and the additional hermetic seal 1402 to form a temporary seal to the internal volume of the encaser 120.
  • the closure element 1425 may comprise a tongue in groove closure and/or other suitable closure that can be used to reseal the encaser 120 between uses. This temporary seal may be used to help prevent moisture intrusion, bacterial contamination, and the accumulation of particulates within the internal volume.
  • the therapeutic composition 106 of the skin therapy system 100 may be solid, semi-solid or liquid at the room -temperature.
  • the therapeutic composition 106 is mud-based.
  • the therapeutic composition 106 is clay -based.
  • the therapeutic composition 106 is wax- based, and the wax may be in a solid, semi-solid or liquid state.
  • therapeutic composition 106 does not comprise wax, and is mostly in a liquid state.
  • the therapeutic composition 106 may be pre-packaged or packaged prior to the commencement of a therapy session such that it is enclosed in the body part shaped encaser 120 of the skin therapy system 100, as disclosed herein. Upon application, the targeted skin area is in direct contact with the therapeutic composition 106.
  • the formulation of the therapeutic composition 106 may vary depending on the skin condition to be treated, therapeutic purposes, or specific portions of a body part shaped encaser 120 of the skin therapy system 100, for example, fingers versus palm, toes versus ankles.
  • the therapeutic composition 106 of the skin therapy system 100 may comprise a hot lotion and/or a cold lotion.
  • the therapeutic composition 106 may comprise shea butter and/or any other moisturizer, emollient, and/or humectant suitable for improving the condition of the skin.
  • the therapeutic composition 106 may comprise glycolic acid for a glycolic peel of the skin.
  • Various embodiments of the therapeutic composition 106 of the skin therapy system 100 may comprise a wax-based composition.
  • the wax may be selected from paraffin wax, soy wax, beeswax, and palm wax.
  • the therapeutic composition 106 is paraffin based. Paraffin utilized in the present embodiments may soften, hydrate and protect the skin and may also be used as a treatment for some skin disorders.
  • the paraffin may be selected from paraffin wax, liquid paraffin oil (also called mineral oil, nujol, adepsine oil, alboline, glymol, medicinal paraffin, or saxol), semi-solid paraffin (also called petroleum jelly, petrolatum, white petrolatum or soft paraffin), and any derivatives thereof.
  • the paraffin wax based therapeutic composition 106 has a melting point temperature in the range between about 46 °C and about 68 °C, between about 44 °C and about 60 °C, between about 42 °C and about 55 °C, or between about 39 °C and about 50 °C.
  • the customary melt time for standard paraffin is approximately 10-15 minutes or longer in a standard non commercial microwave (750-1000 watts) depending on the quantity being heated. Such a period of heating time is too long and thus not ideal. Further, as shown in FIG.
  • the formulations of the therapeutic composition 106 were further modified such that the uniform melting of the therapeutic composition 106 in a body part shaped encaser 120 is achieved.
  • paraffin wax melting time To reduce the melting time of a paraffin based therapeutic composition 106, various nut or seed oils including safflower oil, vitamin E oil, coconut oil, among other oils, were tested for their effects of paraffin wax melting time after being mixed with the paraffin wax. Theoretically, the use of oils helps to lower the initial viscosity of the paraffin composition and accelerates the melting process. However, not all tested oils can achieve that purpose.
  • An ideal melting time for the therapeutic composition 106 of the skin therapy system 100 disclosed here in is between about 1 to 2 minutes depending on the heating sources.
  • a therapeutic composition 106 may be achieved due to coconut oil forming a more solid state in comparison to other oils at typical room temperatures (below about 80 degrees Fahrenheit). Shortened time of melting and re-solidification or gelification is desirable, in that it shortens the preparation time and enables the formation and shaping of the therapeutic composition 106 into a body part shape much easier and faster either during the therapy or before and after the therapeutic composition 106 is enclosed in a body part shaped encaser 120 of the skin therapy system 100 as disclosed herein.
  • a paraffin based therapeutic composition 106 of the skin therapy system 100 as disclosed herein comprises paraffin and one or more nut oils including coconut oil.
  • a paraffin based therapeutic composition 106 of the skin therapy system 100 may comprise paraffin and coconut oil.
  • the therapeutic composition 106 of the skin therapy system 100 may comprise paraffin and at least one of a seed oil and a nut oil.
  • the concentration of paraffin may be in a range of about 25 wt% to about 75 wt%.
  • the at least one of the seed oil and nut oil in the therapeutic composition 106 may comprise coconut oil.
  • the coconut oil may be at a concentration in a range of about 25 wt% to about 75 wt%.
  • the therapeutic composition 106 of the skin therapy system 100 comprises from about 30 wt% to about 60 wt% of coconut oil and from about 40 wt% to about 70 wt% of paraffin.
  • the therapeutic composition 106 of the skin therapy system 100 comprises from about 35 wt% to about 55 wt% of coconut oil and from about 45 wt% to about 65 wt% of paraffin. In one embodiment, the therapeutic composition 106 of the skin therapy system 100 comprises about 50 wt% of coconut oil and about 50 wt% of paraffin.
  • each therapeutic composition 106 may melt and achieve a temperature within the ideal temperature range after the same amount of time exposed to a heating source such as microwave.
  • the palm composition 130 for a hand shaped encaser comprises at least about 25 wt% to about 75 wt% of paraffin and 25 wt% to about 75 wt% of coconut oil; and the finger composition 132 and thumb composition 134 for a hand shaped encaser comprise at least 50 wt% to 70 wt% of paraffin and at least about 30 wt% to about 50 wt% of coconut oil.
  • the therapeutic composition 106 may comprise various cannabinoid-containing extracts of Cannabis (i Cannabis indica and/or Cannabis sativia ) plants for transdermal delivery of the cannabinoids.
  • the cannabinoid may comprise the non-psychotropic alkaloid cannabidiol (also referred to as CBD).
  • the cannabinoid may comprise the non-psychotropic cannabidiolic acid (CBDA).
  • CBDA may be converted to CBD through heating which causes decarboxylation of CBDA.
  • the therapeutic composition 106 may comprise a broad-spectrum CBD, a full-spectrum CBD, an isolate of a CBD, a CBDA, or any combination thereof.
  • the therapeutic composition 106 comprises a broad- spectrum CBD oil.
  • the broad-spectrum CBD may contain THC. Since the melting point of is above 70 °C , the THC remains in the paraffin wax when the therapeutic composition 106 is heated between 35 °C (113 °F) to about 55 °C (131 °F).
  • An advantage of using an isolate CBD is targeting a condition with a specific cannabinoid, without any THC in the isolate CBD.
  • Transdermal delivery of CBD through the CBD-containing therapeutic composition 106 may provide the benefits of topically administered CBD such as alleviating wound-related pain, accelerating wound healing, reducing the need for opioid analgesics for controlling pain in skin conditions.
  • CBD-containing therapeutic composition 106 may also improve conditions of deeper tissues such as peripheral neuropathic pain, fibromyalgia, osteoarthritis, and musculoskeletal pain.
  • CBD may also provide anti-aging and antioxidant benefits to the skin.
  • CBD may also have anti inflammatory properties that may improve skin conditions such as acne, psoriasis, and/or eczema.
  • the anti-inflammatory properties of CBD may compliment the anti inflammatory properties of paraffin itself in the therapeutic composition 106.
  • the benefits of topical CBD are further evidenced by its lack of systemic side effects, its ease of be self-administration by the consumer, and its rapid onset of analgesia.
  • the addition of CBD to the therapeutic composition 106 may retain the desired melting temperature of the therapeutic composition 106 of approximately about 45 °C (113 °F) to about 55 °C (131 °F), as discussed below.
  • the CBD may be stable within a homogenous mixture of the therapeutic composition 106 such that the CBD binds well with seed and/or nut oils, such as coconut oil.
  • the therapeutic composition 106 comprising coconut oil, paraffin, and CBD may be mixed and may maintain efficient dispersion, avoiding phase separation.
  • the therapeutic composition 106 can be produced by mixing of coconut oil with the paraffin at a temperature greater than 50°C but less than 80°C until it homogenized.
  • the CBD oil contains CBD in a concentration of 20 mg/ml to 100 mg/ml.
  • the CBD oil is heated to a temperature of greater than 65°C, which is the melting point of CBD.
  • the heated CBD oil is then added to the homogenized mixture of coconut oil and paraffin, which is heated to a temperature of greater than 65°C. At this temperature, the mixture is homogenized, and the CBD oil can be blended into the coconut oil.
  • Optional additives including, but not limited to, fragrances, colors, emollients, essential oils, oil soluble vitamins and/or anti-oxidants, known in the art, can be added to the homogenized mixture of CBD, coconut oil, and paraffin to create the therapeutic composition 106.
  • the volume between the encaser 120 and the encase liner 116 is filled with the therapeutic composition 106 at a temperature above 60°C.
  • the CBD-containing therapeutic composition 106 may comprise a therapeutically effective amount of CBD.
  • the CBD may comprise a commercially available CBD oil and/or CBD wax.
  • the CBD-containing therapeutic composition 106 may comprise at least approximately 2 milligrams of CBD per kilogram of CBD-containing therapeutic composition 106.
  • the amount of CBD in the CBD-containing therapeutic composition 106 may be approximately 2 to approximately 100 milligrams per kilogram.
  • the amount of CBD in the CBD-containing therapeutic composition 106 may be approximately 50 milligrams within each skin therapy system 100.
  • the therapeutic composition 106 comprises paraffin, coconut oil, and CBD.
  • the therapeutic composition 106 can comprise paraffin, and coconut oil in a ratio in a range from 4:1 to 2: 1 and CBD in a range of 5 mg/kg of a combination of paraffin and coconut oil to 100 mg/kg of a combination of paraffin and coconut oil.
  • the amount of CBD in a single encaser 120 is 5 mg and total of 10 mg for a pair of encasers 120.
  • a paraffin based therapeutic composition 106 of the skin therapy system 100 can comprise paraffin, coconut oil and CBD. In some embodiments
  • the amount of CBD in a single encaser 120 is 5 mg and total of 10 mg for a pair of encasers 120. In some examples, the amount of CBD in a single encaser 120 is 25 mg and total of 50 mg for a pair of encasers 120. In some examples, the amount of CBD in a single encaser 120 is 50 mg and total of 100 mg for a pair of encasers 120. In one example, the amount of CBD in a single encaser 120 is 100 mg and total of 200 mg for a pair of encasers 120.
  • the CBD is transported in the coconut oil through the encase liner 116 and into the skin when the temperature of the therapeutic composition 106 is between 48 °C ( 119 ° F) to about 51 °C (124 ° F) .
  • the heat is the transportation mechanism for moving the CBD from the therapeutic composition 106 to the skin surface of the user.
  • Various embodiments of the CBD-containing therapeutic composition 106 may further comprise various additives such as steroids.
  • the steroid may be 1% hydrocortisone.
  • Therapeutic composition 106 as disclosed herein may further comprise at least one essential oil.
  • at least one essential oil For medical purposes, from about six to about twelve drops of medical grade essential oils may be added to the therapeutic composition 106.
  • a drop of essential oils, as defined herein using the AFNOR-ISO standard for quantifying essential oils, is about 1/20* 11 of one milliliter when utilizing the standard of 20 drops per milliliter of essential oil.
  • the standard for a specific essential oil is different due to viscosity, a single-drop volume may be adjusted accordingly.
  • the essential oils are added and mixed into the therapeutic composition 106 before the therapeutic composition 106 is enclosed in a body part shaped encaser 120 of the skin therapy system 100.
  • the essential oils are added into the therapeutic composition 106 prepackaged in a body part shaped encaser 120 of the skin therapy system 100 upon applying the same to a targeted skin area, such that different essential oils may be used for a specific condition of a specific individual under the therapy.
  • Essential oils and aromatic oils of the therapeutic composition 106 may be selected from peppermint oil, cinnamon leaf oil, lemongrass oil, clove oil, castor oil, orange oil, eucalyptus oil, tea tree oil, wintergreen oil, patchouli oil, lavender, bergamot, sandalwood, chamomile, aldehyde Cl 6, a-terpineol, amyl cinnamic aldehyde, amyl salicylate, anisic aldehyde, benzyl alcohol, benzyl acetate, cinnamaldehyde, cinnamic alcohol, carvacrol, carved, citral, citronellal, citronellol, p-cymene, diethyl phthalate, dimethyl salicylate, dipropylene glycol, eucalyptol, eugenol, iso-eugenol, galaxolide, geraniol, guaiacol, ionone,
  • an essential oil mixture for pain relieving comprises peppermint oil, cinnamon leaf oil, clary sage, and orange oil.
  • an essential oil mixture for anti-fungal and anti -bacterial effects comprises tea tree oil, clove oil, lemon oil, eucalyptus oil and patchouli oil.
  • an essential oil mixture for relaxation comprises lavender, bergamot, sandalwood and chamomile.
  • aromatherapy oils may also be utilized to add further therapeutic effects.
  • the therapeutic composition 106 comprising paraffin and coconut oil, may further comprise at least one aromatic oil.
  • the paraffin based therapeutic composition 106 may further comprise optional additives including, but not limited to fragrances, colors, emollients, and antioxidants, known in the art.
  • the antioxidant may be natural or synthetic. Suitable antioxidants include, but are not limited to, ascorbic acid and its salts, ascorbyl palmitate, ascorbyl stearate, anoxomer, N-acetylcysteine, benzyl isothiocyanate, m- aminobenzoic acid, o-aminobenzoic acid, p-aminobenzoic acid (PABA), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), caffeic acid, canthaxantin, alpha-carotene, beta-carotene, beta-carotene, beta-apo-carotenoic acid, camosol, carvacrol, catechins, cetyl gallate, chlorogenic acid, citric acid and its salts,
  • the antioxidants incorporated into the composition encompass all potential salt and ester forms of the antioxidants in addition to the pure forms of the compound.
  • the antioxidant may comprise a vitamin E compound such as tocopheryl acetate, tocopheryl linoleate, tocopherol nicotinate, tocopheryl succinate, ascorbyl tocopheryl phosphate, dioleyl tocopheryl methylsilanol, tocophersolan, and tocopheryl linoleate/oleate.
  • included in the vitamin E oil are traces of safflower oil, and other oils.
  • the vitamin E formula further comprises the largest amount of sunflower seed oil followed by safflower seed oil, tocopheryl acetate, rice bran oil, almond oil, apricot oil, wheat germ oil and lecithin.
  • the therapeutic composition 106 comprising paraffin at a concentration in a range of about 25 wt% to about 75 wt% and coconut oil at a concentration in a range of about 25 wt% to about 75 wt%
  • the therapeutic composition 106 further comprises from about 2 wt% to 7 wt% of a mixture of antioxidant.
  • the therapeutic composition 106 of the skin therapy system 100 may be a liquid-based composition, such that a solid to liquid, then back to solid phase changes are not involved.
  • a pre-heating or pre-cooling step before application may be required.
  • a pre-heating or pre cooling step before application may not be required.
  • the liquid- based composition comprises a therapeutic composition 106 comprising alpha hydroxy acid including lactic acid and glycolic acid; and/or beta hydroxy acid including salicylic acid, and any combination thereof.
  • liquid based composition comprising alpha hydroxy acid including lactic acid and glycolic acid; and/or beta hydroxy acid including salicylic acid may further comprise essential oils, fragrances, colors, emollients, anti-oxidants, and other additives including absorbent, adsorbent, pH controller, and substances for rehydration known in the art.
  • a liquid based therapeutic composition 106 for the skin therapy system 100 comprises lactic acid, glycolic acid, salicylic acid, lemon oil, polyquaternium-10, PEG-40 hydrogenated castor oil, sodium hydroxide, and one or more antioxidant including vitamin E.
  • suitable essential oils and anti-oxidants for a liquid-based therapeutic composition 106 are described above in detail.
  • This technology also provides a method relating to providing skin treatment utilizing a therapeutic composition 106 contained in a body part shaped encaser 120 amenable to various heating elements to provide liquefaction before use without burning the skin.
  • the method of using the skin therapy system 100 as disclosed herein for skin treatment generally comprises the steps of heating the encaser 120 containing a therapeutic composition 106 using one or more heating elements, applying the unsealed encaser 120 to targeted skin area by attaching the encaser 120 to a body part, and removing the encaser 120 from the targeted skin area at the end of the therapy.
  • paraffin based therapeutic compositions 106 need to be heated to melt prior to application.
  • Paraffin wax typically has a melting point temperature in the range between about 46 °C (114.8 °F) and about 68 °C (154.4 °F).
  • Petroleum jelly based therapeutic compositions 106 have a melting-point usually within a few degrees of human body temperature, which is approximately 37 °C (98.6 °F).
  • Liquid paraffin-based therapeutic composition 106 and other liquid based composition may need to be pre-heated to body temperature for the comfortable feel to the skin upon application.
  • the therapeutic composition 106 enclosed in a body part shaped encaser 120 of the skin therapy system 100 as disclosed herein may require a heating process by a heating element.
  • a heating element may be selected from microwave oven, stove, hot towel cabinet, heating coils, heating pad, heater, heating lamp, warmer, radiator, boiler, steamer (such as a towel steamer), warm water bath, hydrocollator, and any other device or equipment known in the art.
  • the heating element may be portable.
  • the heating element is comprised in the skin therapy system 100.
  • the heating temperature may be provided by a heating element included in the skin therapy system 100, and the temperature of the therapeutic composition 106 may be indicated by touching or temperature indicator attached to the body part shaped encaser 106 of the skin therapy system 100.
  • the melting temperature of a therapeutic composition 106 ranges from about 45 °C (113 °F) to about 55 °C (131 °F).
  • the melting temperature of a therapeutic composition 106 ranges from about 48 °C (119 °F) to about 51 °C (124 °F).
  • the therapeutic composition 106 may comprise paraffin at a concentration of about 25-75 wt%, by weight of the composition, and coconut oil at a concentration of about 25-75 wt% by weight of the composition and have a melting temperature between about 48 °C to about 51 °C, with an even melting of the composition taking place in about 1-5 minutes.
  • the sealed encaser 120 containing the therapeutic composition 106 is opened by cutting, unzipping or tearing the closure 1425 of the encaser 120.
  • the body part is inserted into the encaser 120 such that the targeted skin area is in direct contact with the therapeutic composition 106, through touching, dipping, or being covered by the therapeutic composition 106.
  • the encaser 120 is then attached to the body part using adhesive tape, strap, string elastic band, or tubing for stabilization during the therapy.
  • the application may last for 10 minutes, 20 minutes, 30 minutes, 60 minutes, 120 minutes or longer, or any range of duration in between.
  • the encaser 120 is released from the body part by removing the body part from the encaser 120 comprising the therapeutic composition 106.
  • the method of using the skin therapy system 100 as disclosed herein for skin treatment may further comprise assembling the body part shaped encaser 120.
  • a microwave oven used as a heating element in method 300
  • the following steps may be followed.
  • a first wax-based composition is formulated to be heatable by a microwave energy producer.
  • a second microwave-heatable wax-based composition is formulated to be heatable by a microwave energy producer.
  • at least one body part shaped encaser structured and arranged to encase a body part of a human body is provided.
  • one or more microwave-heatable wax-based composition is encased by spreading the composition into a thin layer in the encaser.
  • each one of such microwave-heatable wax-based composition is formulated to comprise at least one first substance, and at least one second substance; wherein such first substance comprises wax elements; wherein the second substance comprises oil elements.
  • Step 312 indicates that a first microwave- heatable wax-based composition is formulated to comprise a first ratio X of wax elements to the oil elements, and a second microwave-heatable wax-based composition is formulated to comprise a second ratio Y of wax elements to the oil elements.
  • the latent heat of fusion of the resulting first microwave-heatable wax- based composition may be substantially different from the latent heat of fusion of the second microwave-heatable waxy composition.
  • a skin treatment utilizing such wax-based compositions amenable to microwave heating to provide liquefaction before use without skin burning may be provided by adjusting placement and amount of a first microwave-heatable wax-based composition and a second microwave-heatable wax-based composition within a body part shaped encaser to equalize the melting of the wax-based composition to assist prevention of injuring skin tissues of the body part to be treated.
  • FIG. 6B shows an illustrative set of instructions for using a pre-packaged kit/apparatus according to an embodiment of the present technology.
  • single-use wax-based encaser 120 may be provided as a prepackaged kit 400 (See Fig 4 A, FIG. 4B and FIG. 6A and FIG. 6B) comprising a microwavable sealing box 114 comprising at least one single-use glove 102 or single-use boot 104 comprising one or more therapeutic composition 106 and at least one set of instructions 410.
  • the temperature indicator 118 such as temperature activated ink
  • the temperature indicator 118 may be sprayed, printed, stamped, and/or otherwise applied to at least one of the first and second substrates of film 1410, 1415 that form the encaser 120.
  • the encaser liner 116 may be layered between the first and second substrates of film 1410, 1415.
  • a hot compress having an outline of a desired body part shape may be applied to the layered stack of the first and second substrates of film 1410, 1415 and the encaser liner 116.
  • the hot compress may melt the layered stack forming the first hermetic seal 1400 and affixing the encaser liner’s 116 position within the internal volume of the encaser 102 while also creating a first fillable space between the first substrate of film 1410 and a first layer of the encaser liner 116 (top layer) and a second fillable space between the second substrate of film 1415 and a second layer of the encaser liner 116 (bottom layer).
  • the therapeutic composition 106 may be poured or otherwise placed into the two fillable spaces (top and bottom layers).
  • a second hermetic seal may be formed between the first substrate of film 1410 and the first layer of the encaser liner 116 to seal the therapeutic composition 106 in place within the first fillable space (top layer).
  • a third hermetic seal may be formed between the second substrate of film 1415 and the second layer of the encaser liner 116 to seal the therapeutic composition 106 within the second Tillable space (bottom layer).
  • a closure element 1425 may be included between the hand aperture 140 and the additional hermetic seal 1402 to seal off the entire internal volume of the encaser 120 and the internal volume of the encaser liner 116 from the surrounding environment.
  • an exemplary cross-section view of a skin therapy system 100 illustrates various methods of skin therapy.
  • a skin therapy system 100 comprising an encaser 120, an encaser liner 116, and a therapeutic composition 106 positioned in a tillable space between the encaser 120 and the encaser liner 116.
  • the tillable space is a volume defined by the inner surface of the encaser 120 and the outer surface of the encaser liner 116, which are connected at the cuff of the encaser 120.
  • the tillable space is a volume defined by the inner surface of the encaser 120 and the outer surface of the encaser liner 116, which are connected at the cuff of the encaser 120 and connected at the fingertips (and thumb tip) of the encaser 120.
  • a tillable space is located on both of the outer surfaces of the encaser liner 116 and the encaser liner 116 is held in place by the connections to the encaser 120 the fingertips when user pulls a body part (such as, for example a hand) out of the skin therapy system 100.
  • the therapeutic composition 106 is held in the tillable space by the encaser liner 116 and the therapeutic composition 106 is not in contact with a user’s skin 1450.
  • the encaser liner 116 can made of non-woven polypropylene fabric (or an equivalent material), which is permeable to one or more ingredients of the therapeutic composition 106 at an elevated temperature in a range from 45 °C (113 °F) to 55 °C (131 °F).
  • a therapeutic composition 106 comprises paraffin and coconut oil, as described herein, if the therapeutic composition 106 is temperature in a range from 45 °C (113 °F) to 55 °C (131 °F), a portion of the coconut oil is thermally transported 1140 through the encaser liner 116 and onto the skin 1450 of a body part 1460.
  • a therapeutic composition 106 comprises paraffin, coconut oil, and vitamin E, as described herein, if the therapeutic composition 106 is temperature in a range from 45 °C (113 °F) to 55 °C (131 °F), a portion of the coconut oil and the vitamin E is thermally transported 1140 through the encaser liner 116 and onto the skin 1450 of a body part 1460.
  • a therapeutic composition 106 comprises paraffin, coconut oil, and an essential oil, as descried herein, if the therapeutic composition 106 is temperature in a range from 45 °C (113 °F) to 55 °C (131 °F), a portion of the coconut oil and the essential oil is thermally transported 1140 through the encaser liner 116 and onto the skin 1450 of a body part 1460. In these examples, the paraffin is blocked by the encaser liner 116 and the paraffin does not make contact with the skin 1450.
  • the body part 1460 is defined by the skin 1450 on either side of the internal structure 1455 of the body part 1460.
  • the body part can be a finger, a thumb, a hand, a toe, a foot, a part of a leg, or a part of an arm.
  • a method can include providing a skin therapy system 100 comprising an encaser 120, an encaser liner 116, and a therapeutic composition 106 positioned in a tillable space between the encaser 120 and the encaser liner 116 and heating the therapeutic composition 106 at an elevated temperature in a range from 35 °C to 55 °C.
  • the method can include inserting a body part 1460 into an opening of the encaser 120 and contacting skin surface 1450 surrounding the body part 1460with the encaser liner 116.
  • the method can include keeping the skin surface 1450 in contact with the encaser liner 116 while the therapeutic composition 106 at the elevated temperature and thermally transporting 1440 at least one ingredient from the therapeutic composition on to the skin 1450.
  • the method can include blocking the paraffin from reaching the skin 1450.
  • the at least one ingredient can be coconut oil.
  • the at least one ingredient can be vitamin E.
  • the at least one ingredient can be lanolin.
  • the treating the skin can be adding moisture to dry skin 1450 .
  • the treating the skin can reducing cracks in the skin 1450.
  • the treating the skin can be relieving pain from arthritis.
  • the treating the skin can be a skin therapy.
  • an exemplary cross-section view of the skin therapy system 100 illustrates various methods of transdermal delivery of a medicinal.
  • Some embodiments employ various materials for containing heat-stable therapeutic compositions 106 which may be practiced in conjunction with any number of compositions and procedures for treating pain and inflammation of joints and other body parts and the systems described are merely exemplary applications for the technology.
  • Various representative implementations of these embodiments may be applied to any portion of the human body for the treatment of skin, pain, injury, and/or inflammatory medical conditions.
  • the treating the skin can be reducing inflammation in the internal structure 1455 of the body part 1460. Examples of the internal structure 1455 can be a muscle, a tendon, a ligament, or connecting tissue.
  • the thermally transporting 1444 at least one ingredient from the therapeutic composition on to the skin 1450 can include transporting the at least one ingredient through the skin 1450 and into the internal structure 1455 of the body part 1460. Some embodiments can include treating a sprain in the internal structure 1455 of a body part 1460, which can include thermally transporting 1444 at least one ingredient from the therapeutic composition into the internal structure 1455 of the body part 1460.
  • the therapeutic composition 106 can include an medically active ingredient and the medically active ingredient can be thermally transported 1444 into the internal structure 1445 of the body part 1460 and treating at least one of a muscle, a tendon, a ligament, or connecting tissue.
  • a medically active ingredient can be at least one of an anti inflammatory, an antioxidant, a steroid, an essential oil, and combinations thereof.
  • a therapeutic composition 106 comprises paraffin, coconut oil, and a medically active ingredient, as described herein, if the therapeutic composition 106 is temperature in a range from 45 °C (113 °F) to 55 °C (131 °F), a portion of the coconut oil is thermally transported 1140 through the encaser liner 116 and onto the skin 1450 of a body part 1460 and the medically active ingredient is thermally transported 1444 into the skin 1450 and can be thermally transport 1444 into the internal structure 1455 of the body part 1460.
  • a therapeutic composition 106 comprises paraffin, coconut oil vitamin E, and a medically active ingredient, as described herein, if the therapeutic composition 106 is temperature in a range from 45 °C (113 °F) to 55 °C (131 °F), a portion of the coconut oil and the vitamin E is thermally transported 1140 through the encaser liner 116 and onto the skin 1450 of a body part 1460 and the medically active ingredient is thermally transported 1444 into the skin 1450 and can be thermally transport 1444 into the internal structure 1455 of the body part 1460.
  • a therapeutic composition 106 comprises paraffin, coconut oil, an essential oil, and a medically active ingredient, as descried herein, if the therapeutic composition 106 is temperature in a range from 45 °C (113 °F) to 55 °C (131 °F), a portion of the coconut oil and the essential oil is thermally transported 1140 through the encaser liner 116 and onto the skin 1450 of a body part 1460 and the medically active ingredient is thermally transported 1444 into the skin 1450 and can be thermally transport 1444 into the internal structure 1455 of the body part 1460.
  • the paraffin is blocked by the encaser liner 116 and the paraffin does not make contact with the skin 1450.
  • the and a medically active ingredient is CBD.
  • the CBD is transported in the coconut oil through the encase liner 116 and into the skin when the temperature of the therapeutic composition 106 is between 48 °C (119 °F) to about 51 °C (124 °F).
  • the heat is the transportation mechanism for moving the CBD from the therapeutic composition 106 to the skin surface of the user.
  • the heat provided to the skin 1450 by the heated therapeutic composition 106 increases the permeability of the skin 1450, which allows the CBD to penetrate deeper into the skin 1450 (and in some cases into the internal structure 1455) and last longer in the tissue. This enables a larger amount of CBD to reach a treatment as compared to rubbing a CBD oil with the same concentration on to one’s skin at room temperature.
  • Method of treating inflammation comprising proving an encaser 120 having a therapeutic composition 106 comprising comprises paraffin, coconut oil, and CBD, the therapeutic composition 106 positioned between the encase 120 and an encase liner 122.
  • the method can comprise heating the therapeutic composition 106 to a temperature in the between 48 °C (119 °F) to about 51 °C (124 °F) then contacting the encase liner 122 to a surface of skin.
  • the method can comprise applying heat to the surface of the skin to increase permeability of the skin and transporting an oil comprising CBD from the therapeutic composition 106 into the skin.
  • the amount of CBD in the therapeutic composition 106 can be from 5 mg to 100 mg.
  • the oil can also comprise coconut oil.
  • the ratio of coconut oil to CBD in the therapeutic composition 106 is in a range from 40:1 to 5:1 by weight.
  • a method of relieving inflammation and/or pain includes provide a skin therapy system 100 comprising an encaser 120, an encaser liner 116, and a therapeutic composition 106 comprising an therapeutic amount of CBD positioned in a Tillable space between the encaser 120 and the encaser liner 116 and thermally transporting the therapeutic amount of CBD to a targeted inflammation site in the internal structure 1455 of the body part 1460
  • a method of relieving stress, anxiety, and/or PSD includes provide a skin therapy system 100 comprising an encaser 120, an encaser liner 116, and a therapeutic composition 106 comprising an therapeutic amount of CBD positioned in a Tillable space between the encaser 120 and the encaser liner 116 and thermally transporting the therapeutic amount of CBD into at least one blood vessel in the internal structure 1455 of the body part 1460.
  • a method of delivering antioxidants includes provide a skin therapy system 100 comprising an encaser 120, an encaser liner 116, and a therapeutic composition 106 comprising an therapeutic amount of CBD positioned in a fillable space between the encaser 120 and the encaser liner 116 and thermally transporting the therapeutic amount of CBD into at the internal structure 1455 of the body part 1460.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un système pratique et hygiénique de traitement cutané comprenant un étui, une ou plusieurs compositions thérapeutiques, un moyen d'étanchéité et d'éventuels accessoires. L'invention concerne également un procédé d'utilisation d'un tel système de traitement cutané. Le système de traitement cutané et l'utilisation de celui-ci permettent de fournir une approche thérapeutique effective, efficace et sûre.
PCT/US2020/026788 2019-04-05 2020-04-05 Systèmes de traitement cutané WO2020206404A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2021560289A JP2022522232A (ja) 2019-04-05 2020-04-05 皮膚治療システム
KR1020217036255A KR20210150490A (ko) 2019-04-05 2020-04-05 피부 치료요법 시스템
EP20783239.5A EP3946548A4 (fr) 2019-04-05 2020-04-05 Systèmes de traitement cutané
CA3135986A CA3135986C (fr) 2019-04-05 2020-04-05 Systemes de traitement cutane
CN202080043240.3A CN113993573A (zh) 2019-04-05 2020-04-05 皮肤治疗系统

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830196P 2019-04-05 2019-04-05
US62/830,196 2019-04-05

Publications (2)

Publication Number Publication Date
WO2020206404A1 WO2020206404A1 (fr) 2020-10-08
WO2020206404A9 true WO2020206404A9 (fr) 2021-08-26

Family

ID=72666299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/026788 WO2020206404A1 (fr) 2019-04-05 2020-04-05 Systèmes de traitement cutané

Country Status (6)

Country Link
EP (1) EP3946548A4 (fr)
JP (1) JP2022522232A (fr)
KR (1) KR20210150490A (fr)
CN (1) CN113993573A (fr)
CA (1) CA3135986C (fr)
WO (1) WO2020206404A1 (fr)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2210618A (en) * 1939-09-15 1940-08-06 Cyr William H De St Method and apparatus for treating the skin
US4122554A (en) * 1977-03-28 1978-10-31 Stager Phyllis H Disposable cosmetic glove
US5050596A (en) * 1989-12-12 1991-09-24 Packaging Electronics & Devices Corp. Reusable and microwavable hot or cold therapy mitt and method of manufacture
US5614202A (en) * 1994-05-17 1997-03-25 Defina; Linda E. Moisturizing glove
AU8006200A (en) * 1999-10-08 2001-04-23 Procter & Gamble Company, The Applicator having a temperature changing element for distributing a product ontoa target surface
US7255506B2 (en) * 2000-06-02 2007-08-14 The Procter & Gamble Company Semi-enclosed applicator for distributing a substance onto a target surface
US20010048936A1 (en) * 1999-12-22 2001-12-06 Prenovitz Melvin B. Gloves and booties for dispensing skin treating agents
FR2822711B1 (fr) * 2001-03-28 2003-06-13 Oreal Dispositif de traitement comportant une enveloppe definissant une cavite dans laquelle peut-etre engagee une partie du corps
US20050202068A1 (en) * 2004-03-12 2005-09-15 Hasenoehrl Erik J. Disposable nonwoven mitt
US20070206984A1 (en) * 2006-03-06 2007-09-06 Redipax, Ltd Glove for dispensing a substance therefrom to a surface
US20090149925A1 (en) * 2007-12-05 2009-06-11 Kimberly-Clark Worldwide, Inc. Temperature Indicator for Warming Products
US8574281B2 (en) * 2008-09-12 2013-11-05 Nicholas Vracknos Method and apparatus of paraffin treatment of the skin
CN103370061B (zh) * 2011-10-17 2016-04-13 帕拉芬国际有限责任公司 皮肤治疗系统
JP5256537B1 (ja) * 2012-12-05 2013-08-07 進一 塚本 手又は足をケアするケア用品

Also Published As

Publication number Publication date
KR20210150490A (ko) 2021-12-10
JP2022522232A (ja) 2022-04-14
EP3946548A1 (fr) 2022-02-09
WO2020206404A1 (fr) 2020-10-08
CA3135986C (fr) 2024-01-23
EP3946548A4 (fr) 2023-02-15
CA3135986A1 (fr) 2020-10-08
CN113993573A (zh) 2022-01-28

Similar Documents

Publication Publication Date Title
CA3101792C (fr) Systemes de therapie de la peau
US20220096805A1 (en) Skin therapy systems
CN100508960C (zh) 用于为身体的部位提供治疗的具有彼此可拆卸地固定在一起的两个贴片的皮肤系统
WO2010001391A1 (fr) Application dermique de vasoconstricteurs
US20140052080A1 (en) Disposable and portable garment for treating hands or feet
MXPA04004672A (es) Manga y parche analgesico microencapsulado de uso topico para el tratamiento del dolor.
US20190232033A1 (en) Skin therapy systems
CA3135986C (fr) Systemes de traitement cutane
US20130238065A1 (en) Epidermal cooling
KR101860726B1 (ko) 캡사이신을 포함하는 열가소성 탄성체 겔 조성물을 사용한 다이어트용 패치
CN106659815A (zh) 包括凉爽体系的吸收制品
CN1331517C (zh) 白芨烧伤贴
KR102312099B1 (ko) 복부 온열 패치
KR101343323B1 (ko) 히팅 팩용 아로마조성물 및 이를 포함하는 히팅 팩
KR20110028466A (ko) 국소 조성물을 위한 전달 제품
JP2006290830A (ja) 皮膚閉鎖環境用エアゾール組成物及びエアゾール
CN104984021A (zh) 一种止痒消炎水及其制备方法
US20120022471A1 (en) Cosmetic Composition for th Ecare and Correction of Telangiectasias
RU2463931C1 (ru) Способ профилактики периоперационной гипотермии и гипертермии при проведении операции под наркозом
CN103285157B (zh) 一种治疗中性和油性皮肤冻疮的药物及其制作方法
JP3220025U (ja) ダイエット用パッチ
CN113786424A (zh) 一种用于治疗黄体酮注射导致的臀部硬结的中药组合物及其制备方法与应用
CN105213240A (zh) 紧肤按摩霜
DE102016007892A1 (de) Das reagierende und schützende Pflaster
JPH07136233A (ja) 温灸具

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20783239

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021560289

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3135986

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217036255

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2020783239

Country of ref document: EP

Effective date: 20211105